drugset
drugset / Trial / NCT03770780

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

NCT03770780 ↗

Phase 1 Completed 19 enrolled Supernus Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindBasic science

Summary

This study is a phase 1, double-blind, placebo-controlled crossover study of SAGE-718 using a ketamine challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic response using magnetic resonance imaging in healthy subjects

Timeline

Start
2018-11-12
Primary completion
2019-03-08
Completion
2019-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalzanemdor Small molecule — —

Indications

No indication recorded.